0000000000393586

AUTHOR

Gianni Virgili

0000-0002-9960-2989

showing 6 related works from this author

What Do We Really Know about the Effectiveness of Glaucoma Interventions?

2021

Purpose To identify systematic reviews of interventions for glaucoma conditions and to assess their reliability, thereby generating a list of potentially reliable reviews for updating glaucoma practice guidelines. Design Cross-sectional study. Participants Systematic reviews of interventions for glaucoma conditions. Methods We used a database of systematic reviews and meta-analyses in vision research and eye care maintained by the Cochrane Eyes and Vision United States Satellite. We examined all Cochrane systematic reviews of interventions for glaucoma conditions published before August 7, 2019, and all non-Cochrane systematic reviews of interventions for glaucoma conditions published betwe…

medicine.medical_specialtyIntraocular pressureTrabeculoplastygenetic structuresMinimally invasive glaucoma surgerybusiness.industrymedicine.medical_treatment010102 general mathematicsGlaucomaGeneral MedicineEvidence-based medicinemedicine.disease01 natural scienceseye diseases03 medical and health sciences0302 clinical medicineProstaglandin analogSystematic review030221 ophthalmology & optometrymedicineTrabeculectomysense organs0101 mathematicsIntensive care medicinebusinessOphthalmology Glaucoma
researchProduct

How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016

2020

Purpose. To describe intravitreal anti-VEGF drug and dexamethasone use in four Italian regions. Methods. Four regional claims databases were used to measure drug prevalence, compare dosing intervals to those recommended in the summary of product characteristics (SPC), and identify switchers. Bilateral treatment and diabetic macular edema (DME) coding algorithms were validated, linking claims with a sample of prospectively collected ophthalmological data. Results. Overall, 41,836 patients received ≥1 study drug in 2010–2016 (4.8 per 10,000 persons). In 2016, anti-VEGF drug use ranged from 0.8 (Basilicata) to 5.7 (Lombardy) per 10,000 persons while intravitreal dexamethasone use ranged from 0…

MaleVascular Endothelial Growth Factor A0301 basic medicineintravitrealAngiogenesis Inhibitorsalgorithm.0302 clinical medicineMedicineSummary of Product Characteristicsmedia_commonAged 80 and overDrug ImplantsvalidationLaser CoagulationRGeneral MedicineMiddle AgedItalyanti-VEGF030220 oncology & carcinogenesisMedicineFemaleclinical dataoriginal articleResearch Articlemedicine.drugDrugmedicine.medical_specialtyArticle Subjectmedia_common.quotation_subjectMEDLINEdexamethasonePharmacyMacular EdemaGeneral Biochemistry Genetics and Molecular BiologyInsurance Claim Review03 medical and health sciencesRanibizumabInternal medicineHumansDosingDexamethasoneAgedDiabetic RetinopathyGeneral Immunology and MicrobiologySettore MED/30 - Malattie Apparato Visivobusiness.industryclaims database030104 developmental biologydrug utilisationMacular Edema; Ranibizumab; Laser CoagulationImplantRanibizumabbusinessBioMed Research International
researchProduct

Evolving European guidance on the medical management of neovascular age related macular degeneration

2006

BACKGROUND: Until recently, only two options were available for the treatment of choroidal neovascularisation (CNV) associated with age related macular degeneration (AMD)-thermal laser photocoagulation and photodynamic therapy with verteporfin (PDT-V). However, new treatments for CNV are in development, and data from phase III clinical trials of some of these pharmacological interventions are now available. In light of these new data, expert guidance is required to enable retina specialists with expertise in the management of AMD to select and use the most appropriate therapies for the treatment of neovascular AMD. METHODS: Consensus from a round table of European retina specialists was obt…

medicine.medical_specialtygenetic structuresBevacizumabAntibodies Monoclonal HumanizedTriamcinolone AcetonideMacular DegenerationCellular and Molecular NeuroscienceRanibizumabOphthalmologymedicineHumansPregnadienediolsEvidence-Based Medicinemedicine.diagnostic_testbusiness.industryAntibodies MonoclonalAptamers NucleotideMacular degenerationFluorescein angiographymedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesSensory SystemsOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyPerspectivesense organsAnecortave acetateChoroidRanibizumabmedicine.symptombusinessmedicine.drugBritish Journal of Ophthalmology
researchProduct

Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southe…

2022

Describe drug utilisation and clinical outcomes of intravitreal anti-VEGF drug and dexamethasone use in the real-world setting in Southern Italy using data from multi-centre study of retinal disease. Clinical data of retinal disease patients treated with anti-VEGF drugs and dexamethasone implant in 6 out-patient ophthalmology centres from Southern Italy were collected by means of an electronic case report form. Patients receiving at least one intravitreal injection/implant of the study drugs were followed for up to two years and described in terms of demographics and clinical characteristics. Drug utilisation patterns were described. A sign-rank test was used to compare clinical data on vi…

MaleVascular Endothelial Growth Factor Agenetic structuresPharmacology &ltPHARMACOLOGY diabetic macular edema &ltbiostatisticsAngiogenesis InhibitorsDexamethasoneMacular DegenerationCATARACTRetinal DiseasesRanibizumabRetinal Vein OcclusionHumansProspective StudiesRETINAAgedAged 80 and overPharmacologySettore MED/30 - Malattie Apparato Visivopathologic myopiaGeneral MedicineMiddle AgedBevacizumabOphthalmologyLENSRETINA epidemiology / biostatistics pathologic myopia retina - medical therapies &ltIntravitreal InjectionsPharmacology diabetic macular edema RETINA epidemiology biostatisticsLENSCATARACTpathologic myopiaFemaleepidemiologydiabetic macular edemaEuropean Journal of Ophthalmology
researchProduct

Risk of Death Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: A Systematic Review and Meta-analysis.

2020

Importance Although intravitreal anti–vascular endothelial growth factor (VEGF) treatment represents the first-line therapy for many retinal diseases, the issue of their systemic safety is debatable. Objectives To assess whether intravitreal anti-VEGF therapy might be associated with increased risk of mortality and which variables are associated with the increase. Data Sources PubMed, MEDLINE, and Embase databases, the Cochrane Library, and ClinicalTrials.gov were systematically searched from inception to May 6, 2019. Study Selection Randomized clinical trials comparing intravitreal anti-VEGF treatment with control groups and with follow-up of at least 6 months were selected. Data Extractio…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyDatabases FactualMEDLINEAngiogenesis InhibitorsCochrane LibraryMacular Edemalaw.inventionRandomized controlled triallawFrequentist inferenceInternal medicineCause of DeathRetinal Vein OcclusionMedicineHumansanti-VEGF therapyrisk of mortality anti-vascular endothelial growth factor mortalityCause of deathOriginal InvestigationRandomized Controlled Trials as TopicDiabetic Retinopathybusiness.industryMortality rateOdds ratioChoroidal NeovascularizationOphthalmologyMeta-analysisIntravitreal InjectionsWet Macular DegenerationbusinessJAMA ophthalmology
researchProduct

Magnitude, temporal trends, and projections of the global prevalence of blindness and distance and near vision impairment: a systematic review and me…

2017

PubMed: 28779882

AFRICAPopulation ageingmedicine.medical_specialtyVisual acuity[SDV]Life Sciences [q-bio]PopulationVisual impairmentVision DisordersVisual AcuityEYEBlindnessGlobal Health03 medical and health sciences0302 clinical medicineSDG 3 - Good Health and Well-being[SDV.IDA]Life Sciences [q-bio]/Food engineeringPrevalenceJournal ArticleGlobal healthHumansMedicineVISUAL IMPAIRMENT[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineering030212 general & internal medicineeducationPublic Environmental & Occupational Healtheducation.field_of_studyScience & Technologybusiness.industryMORTALITYPublic healthlcsh:Public aspects of medicineMedicine (all)COSTlcsh:RA1-1270General MedicinePresbyopiamedicine.diseaseVision Loss Expert Group3. Good healthMeta-analysis030221 ophthalmology & optometry/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingHEALTHmedicine.symptombusinessLife Sciences & BiomedicineDemography
researchProduct